Amarin Corporation plc (Nasdaq: AMRN) has completed dosing and pharmacokinetic sampling in a study to test a fixed-dose combination of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE